Participating Companies

4SC AG
An epigenetic focused company developing small molecule drugs for the treatment of cancer and autoimmune diseases. The company’s lead compound, Resminostat, is focused on Cutaneous T Cell Lymphoma but has unpartnered assets for Hodkins Lymphona, Colorectal Cancer, and HCC. [more information]

Ability Pharmaceuticals, SL
ABTL0812 has been granted Orphan Drug Designation (ODD) for neuroblastoma, pancreatic cancer and for biliary tract cancer by FDA and EMA, and the drug has a sales potential over €2.5 billion in 2025, with a market share over 80% in selected cancer types. [more information]

Abliva Ab
[ABLI-SE]
Focused on rare and severe primary mitochondrial diseases (PMD). KL1333, a NAD+ regulator, to accelerate into pivotal studies in 2H21 based on positive FDA feedback; initial results from Ph1b in PMD patients exp. in 1Q21. NV354, an energy replacement therapy for Leigh Syndrome, in IND-enabling studies. [more information]

Adrenomed AG
Precision medicine, cardiovascular and Sepsis, Adrecizumab Ph 2, biomarker-guided, monoclonal antibody for septic shock; final data released late November:
Early application of Adrecizumab leads to a rapid and statistically significant improvement of fluid balance, systemic organ function and > 50% relative reduction of all cause mortality after 28 days and 90 days compared to placebo on top of SoC.
[more information]

Affibody
Proprietary Affibody® molecules and Albumod platforms. Lead candidate is an IL-17 with positive Ph2 52wk data in psoriasis and Ph2 IND for lead indication uveitis will be filed in Q1 2021. In addition, the company has an ongoing relationship with Inmagene in China. Backed by Investor AB. [more information]

Alligator Bioscience
[ATORX:ST]
SKr442 MM MCap
Alligator specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. In immunotherapy, the patients´ immune system is activated to cure cancer. The term tumor-directed means that the drug is administered or designed such that the pharmacological effect is localized to the tumor. [more information]

AM-Pharma B.V.
Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. [more information]

Bachem Holding AG
Bachem is a leading and innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. Headquartered in Switzerland and with locations in Europe, the USA and Asia, Bachem operates internationally and has 50 years of experience and expertise that is unique in the industry. [more information]

BerGenBio
[BGBIO:OS]
NKr2,779 MM MCap
Developing first-in-class selective Axl kinase inhibitors for liquid and solid cancers, lead candidate is bemcentinib (BGB324) in four company-sponsored trials. [more information]

Cantargia AB
[CANTA:ST]
SKr5,320 MM MCap
The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. Cantargia's other project, CAN10, is in the preclinical phase and is aiming to develop an IL1RAP binding antibody blocking IL-1, IL-33 and IL-36 - optimised for the treatment of systemic sclerosis and myocarditis. [more information]

Cellestia Biotech AG
The company's drugs offer a mode of action for the treatment of NOTCH dependent leukemias, lymphomas and solid tumors through oral medication, enabling patients to get efficient treatment and ensure a fast recovery. Cellestia is completing a Phase l first-in-man clinical trial with CB-103 treating cancer patients in the EU. [more information]

COSMO Pharmaceuticals N.V.
[C43.F]
Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders. [more information]

Crescendo Biologics
Crescendo Biologics is a clinical stage company developing T cell enhancing therapeutics.
Crescendo’s lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific. CB307’s unique format delivers tumour-specific killing, while avoiding systemic toxicity, and can be applied to a broad range of PSMA-positive cancer indications. It is designed to cause the proliferation of tumour-specific T cells, creating a safe, broad, longer-lasting anti-tumour response and will be in the clinic in early 2021. [more information]

Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. [more information]

Enterome
Enterome is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases. [more information]

eTheRNA immunotherapies
eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy. It is developing mRNA based cancer immunotherapies from its unique TriMix platform. Both are being developed outside the US. [more information]

Ethris GmbH
We are rapidly approaching in vivo proof of concept for generating therapeutic antibodies against COVID-19 in the lung through a partnered program while advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients’ lives [more information]

Evotec AG
[EVTA:FF]
US$5,150 MM MCap
The EVT Innovate segment is an internal drug discovery platform with over 70 product opportunities and expertise across diseases areas. [more information]

Exscientia
Exscientia is applying AI and big data processing to accelerate drug discovery and development. [more information]

Heidelberg Pharma AG
[HPHA:DB]
€252 MM MCap
Heidelberg Pharma AG (HPHA, Frankfurt Stock Exchange), based in Ladenburg, Germany, is a leading biotech company pioneering the use of its ATAC (Antibody Targeted Amanitin Conjugate) platform to develop novel cancer treatments with a unique mode of action effective at specifically killing both inactive and dividing cancers cells and overcoming tumor resistance mechanisms. [more information]

HepaRegeniX
HepaRegeniX is developing novel therapies for the treatment of acute and chronic liver diseases. Since its start in 2017, HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4). [more information]

Horama
The company's lead candidate is HORA-PDE6B, which is in Phase I/II clinical trials with an indication in PDE6B retinitis pigmentosa. The second product will enter in the clinic in H1 2019 The company raised EUR 22.5 million of Series B venture funding from Kurma Partners, Pontifax Venture Capital, Fund+ on November 8, 2017. [more information]

Imcyse
Developing disease specific immune therapies to treat severe, chronic auto-immune, inflammatory, allergic, infectious diseases and tumors. [more information]

Immune Regulation Ltd
These therapies exhibit a short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies. [more information]

Immunicum AB
[IMMU:ST]
SKr1,173 MM MCap
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Immunicum's goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. [more information]

InteRNA Technologies
InteRNA Technologies provides drug discovery and development services. [more information]

Kiadis Pharma N.V.
[KDS-AMS]
NK-cell platform administered as adjunct I-O on top of HSCT. Launched FIH POC trial in r/r AML patients (Feb 2020); set to launch additional HSCT trial later in 2020 w/interim data exp 2021. Presenting new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients at EBMT in 2020. Established POC in 37 patients total. [more information]

Macrophage Pharma
A private UK based biotechnology company focused on treating human disease by reprogramming macrophage function through transcriptional reprogramming and targeted drug-delivery leveraging its proprietary Esterase Sensitive Motif™ (ESM™) platform. [more information]

MiNa Therapeutics
Developer of therapeutic medicines designed to harness gene activation mechanisms through small activating RNA. The company's technology and clinical know-how transform the therapy landscape of cancer and other severe diseases, enabling doctors and physicians to cure cancer and other severe diseases and develop new medicines that restore normal function to patients' cells. [more information]

Minoryx Therapeutics
Oral PPARg agonist, MIN-102, in Pivotal Ph 2/3 for X-linked ALD and Ph 2 Friedrich’s Ataxia; data for both expected by end of 2020. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc
[more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH (positive Ph2b interim results) and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Nouscom AG
Nouscom is a next-generation immunotherapy company developing genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. The company has offices in Basel and Rome. [more information]

NovaGo Therapeutics
NovaGo Therapeutics is a Swiss development stage biotech company focused on human antibody therapeutics targeting blood vessel and nerve growth. [more information]

Oncimmune
[ONC:LN]
Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners. [more information]

Pharming Group NV
[PHARM:AS]
€702 MM MCap
recent in-license from Novartis of late stage drug Leniolisib for APDS (ultra-rare immunodeficiency condition), rhC1INH for new larger indications including COVID-19, pre-eclampsia, AKI and additional pipeline product from technology platform: recombinant alpha-Glucosidase for Pompe disease. [more information]

Prilenia
He is the former President of Global R&D and Chief Scientific Officer at Teva Pharmaceuticals, where he led the development of ~35 new products towards approval in several major markets, predominantly in CNS. Prilenia is focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. [more information]

Ryvu Therapeutics
[RVU:WAR]
Potential first in class CDK8 inhibitor for leukemias, lymphomas, and solid tumors in Ph1b in AML and high-risk MDS, PIM/FLT3 kinase inhibitor in Ph 1/2 in AML (partnered w Menarini). Data in 2020. Early stage pipeline addressing emerging solid tumor targets. [more information]

Scenic Biotech
Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene. It is building a pipeline of disease modifying therapeutics to treat devastating diseases including inherited rare diseases and cancer. [more information]

Sensyne Health
[SENS]
US$1,318 MM MCap
Sensyne Health operates as a digital healthcare company. [more information]

SNIPR BIOME
Operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases. The company uses CRISPR technology that can subvert elements of the endogenous bacterial CRISPR machinery to eliminate hazardous bacteria in vivo, providing the health professionals with medicines that selectively target and kill bacteria with specific DNA sequences. [more information]

Valbiotis
[ALVAL-FR]
At the start of 2020, Valbiotis signed a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, first active substance in the pipeline (an innovative and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics). [more information]

Versantis
Versantis is a phase 2a pharmaceutical company developing a new generation of orphan medicines to revolutionize the care of patients with liver diseases. Versantis is developing its lead candidate, VS-01, as a first-line medication for the acute support of cirrhotic and metabolic decompensations. VS-01 received Orphan Drug designation from both FDA and EMA. [more information]

Vivoryon
[PRBGF]
US$119 MM MCap
Vivoryon's programs are based on dedicated research, top-level discovery and determined development. The company develops first-in-class medicines that target post-translational modifying enzymes. The pipeline contains several product candidates across various stages of development, focused on Alzheimer’s Disease and oncology. [more information]